Managing Moderate-to-Severe Atopic Dermatitis in Adults: Pathology-Based, Targeted Therapies

Jointly provided by Med Learning Group and Ultimate Medical Academy/CCM.

Supported by an educational grant from Genzyme, a Sanofi Company and Regeneron Pharmaceuticals.

Scroll to the Bottom of this Information to Begin this Course

Release date: February 24, 2017

Valid through: February 24, 2018

Specialty: Dermatology

Topic: Atopic Dermatitis

Media: Internet

Estimated Time to Complete Activity: 60 minutes

Target Audience

This activity is intended for medical dermatologists, nurses and other healthcare professionals involved in the management of patients with atopic dermatitis.

Program Overview

This case-based enduring activity will cover the long-term treatment and management of patients with atopic dermatitis (AD).

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Explain how dysfunction of specific immunologic factors and pathways contributes to the pathophysiology of moderate-to-severe atopic dermatitis (AD) in adults.
  • Review approaches for the assessment and diagnosis of moderate-to-severe AD in adults that account for biomarkers, comorbidities, and the overall disease burden.
  • Discuss proactive versus reactive approaches for the management of moderate-to-severe AD in adults.
  • Review the challenges posed by traditional standard-of-care therapies and the efficacy and safety of new and emerging treatment options.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit
  • Nurses — 1.0 ANCC Credit Hour

All other healthcare professionals completing this course will be issued a statement of participation.

Faculty

Zelma Chiesa Fuxench, MD

Zelma Chiesa Fuxench, MD

Assistant Professor of Dermatology
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Physician Continuing Medical Education

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

Credit Designation

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with atopic dermatitis.

Accreditation Statement

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

AAD Recognized Credit Statement

Med Learning Group’s “Managing Moderate-to-Severe Atopic Dermatitis in Adults: Pathology-Based, Targeted Therapies” #65309 is recognized by the American Academy of Dermatology for 1.0 AAD Recognized Credits and may be used toward the AAD CME Award.

Credit Designation

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

Disclosures of Conflicts of Interest

In accordance with the Accreditation Council for Continuing Medical Education (ACCME)Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Zelma Chiesa Fuxench, MD, in the past 12 months, Dr. Chiesa Fuxench has served as:

  • Principal investigator for atopic dermatitis related clinical trials (Regeneron, Tioga and Vanda pharmaceuticals)
  • Consultant for the National Eczema Association and Asthma and Allergy Foundation of America

Disclosure of Unlabeled Use

Med Learning Group requires that faculty participating in any CME/CNE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

Instructions for Participation and Credit

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Submit the evaluation form to the Med Learning Group.

You will receive your certificate for download immediately, you will also get an email reminder.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser, this list includes the current versions of Mircrosoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.

Disclaimer

Med Learning Group makes every effort to develop CME activities that are scientifically based.This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

Participation Statement

This educational activity provides training necessary for licensed attendees to maintain state licensing requirements. The tuition for this educational activity is subsidized in part by unrestricted educational grants, including for those attendees who have successfully completed the state licensing requirements for their respective fields. This subsidy is reflected in the registration fees for this activity.

Content - Copyright © 2017 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.